Drug Research
IGBA- 2022 WHO Biosimilar Roadmap Facilitates Accessibility
According to the new whitepaper Embracing Science with Confidence: Adopting the Revised 2022 WHO Biosimilars Guideline from the International Generic and Biosimilar Medicines Association (IGBA), the framework provides a fantastic opportunity to re-evaluate how regulatory standards can better progress...
Drug Research
GHIT Fund Invests ¥790M On Neglected Tropical Disease Items
Two neglected tropical illnesses, lymphatic filariasis and onchocerciasis, will receive a combined investment of about 790-million-yen ($5.3 million) from the Global Health Innovative Technology (GHIT) Fund in Japan.
The parasitic worms that cause lymphatic filariasis, also known as elephantiasis, and...
Drug Research
Pharma-Expansion In Africa Necessitates Homegrown Investment
The growth of the domestic pharmaceutical industry and a reduction in reliance on imports might be facilitated by funding AI-based research and development and focusing on the key diseases that impact people in Africa, experts suggested at a recent...
Drug Research
The EMA Endorses Controls On Immune-Regulating Medicines
Due to safety concerns, advisors to the European Medicines Agency on November 11th suggested restricting the use of a class of frequently prescribed anti-inflammatory medications. This recommendation follows a comparable but more stringent decision made by American authorities last...
Drug Research
Australia Allows Faecal Transplants To Restore Gut Health
Australia is the first country in the world to have awarded regulatory approval for faeces transplants.
The healthy genetic material for this donation comes from the microbiomes of poop donors, who must meet a set of requirements. It has been...
Drug Research
Legal, Compliance Collab Between ProductLife And EIT Health
ProductLife Group (PLG), a supplier of regulation and compliance solutions for the life sciences sector, has joined the Venture Centre of Excellence, EIT Health's regulatory hub.
In order to help early-stage biotech, medtech, and digital health start-ups expedite their path...
Drug Research
NHS Permits Potentially Life-Saving Breast Cancer Medicine
The confidential agreement reached by the NHS and the manufacturer is expected to assist up to 1,600 women annually who have high-risk, triple-negative breast cancer. When combined with chemotherapy, pembrolizumab (trade name Keytruda®) reduces the likelihood of breast cancer...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read